Three things to know:
1. The company’s subsidiary Kuros Biosciences BV also secured a patent for developing an osteoinductive calcium phosphate, further bolstering its orthobiologics portfolio.
2. Kuros develops Fibrin-PTH, a natural fibrin-based healing matrix with an immobilized targeted bone growth factor. It is designed to apply onto and around an intervertebral body fusion device as a gel.
3. Fibrin-PTH is undergoing a Phase 2a clinical trial for single level transforaminal lumbar interbody fusion procedures in patients with degenerative disc disease, with autograft as the comparator.
More articles on devices:
8 of the biggest whistleblower cases in spine, orthopedics this year
Outpatient joint replacements to ‘skyrocket over next 10 years,’ says Dr. Richard Berger
Centinel Spine founder leaves to grow other business; Steven Murray named CEO
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.